Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by shadowcatcheron Apr 12, 2012 6:08pm
261 Views
Post# 19788115

More insider buying

More insider buying

https://canadianinsider.com/node/7?menu_tickersearch=BRD

Apr 11/12Apr 11/12Burgess, HarryDirect OwnershipCommon Shares10 - Acquisition in the public market10,000
.740
Apr 11/12Apr 11/12Legatto, JonDirect OwnershipCommon Shares10 - Acquisition in the public market6,900
.720
Apr 11/12Apr 11/12Legatto, JonIndirect OwnershipCommon Shares10 - Acquisition in the public market7,360
.720
Apr 3/12Apr 2/12Gill, Derrick EdwinDirect OwnershipCommon Shares10 - Acquisition in the public market20,000
.770
Apr 3/12Apr 2/12Dawe, Wade K.Direct OwnershipCommon Shares10 - Acquisition in the public market50,000
.780
Apr 2/12Mar 30/12Nicholson, Jennifer LynnControl or DirectionCommon Shares10 - Acquisition in the public market12,500
.788
Apr 2/12Mar 30/12Nicholson, Jennifer LynnControl or DirectionCommon Shares10 - Acquisition in the public market12,500
.789
Apr 2/12Mar 30/12Hatfield, Dana MurrayDirect OwnershipCommon Shares10 - Acquisition in the public market10,000
.800
Apr 2/12Mar 30/12Hatfield, Dana MurrayDirect OwnershipCommon Shares10 - Acquisition in the public market20,000
.770
Apr 2/12Mar 30/12Dawe, Wade K.Direct OwnershipCommon Shares10 - Acquisition in the public market50,000
.780

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities